Regeneron Pharmaceuticals, Inc. (REGN) Q3 2024 Earnings Call Transcript Summary
Regeneron Pharmaceuticals, Inc. (REGN) Q3 2024 Earnings Call Transcript Summary
Continued growth for Libtayo and US growth of total EYLEA HD and EYLEA also contributed significantly to revenue.The following is a summary of the Regeneron Pharmaceuticals, Inc. (REGN) Q3 2024 Earnings Call Transcript:
以下是再生元製藥公司（REGN）2024年第三季度業績會議呼叫成績單摘要：
Financial Performance:
金融業績：
Regeneron reported Q3 2024 total revenue of $3.72 billion, an 11% increase year-over-year primarily driven by higher collaboration revenues with Sanofi and strong performance of Dupixent.
Q3 net income per share increased by 8% to $12.46 on a net income of $1.5 billion.
Continued growth for Libtayo and US growth of total EYLEA HD and EYLEA also contributed significantly to revenue.
再生元報告2024年第三季度總營業收入爲37.2億美元，同比增長11％，主要受益於與賽諾菲安萬特合作收入增加以及杜必信表現強勁。
第三季度每股淨收入增長8％，至12.46美元，淨利潤爲15億美元。
Libtayo持續增長，美國EYLEA HD和EYLEA的總體增長也對營業收入有重大貢獻。
Business Progress:
業務進展：
Regeneron continues to focus on developing its commercial performance and advancing its broad clinical pipeline across therapeutics areas.
Pharmaceutical launches, including EYLEA HD and Dupixent continued approvals, such as Dupixent for COPD with eosinophilic phenotype, further demonstrate substantial market grasp and net patient reach.
再生元繼續專注於發展其商業績效，並在治療領域的廣泛臨床管道方面取得進展。
藥品推出，包括EYLEA HD和杜必信的持續批准，例如用於具有嗜酸性粒細胞特徵的COPD的杜必信，進一步展示了對市場的重大掌握和對患者的淨分享。
Opportunities:
機會：
Dupixent's extended indication for COPD offers a considerable market expansion potential, given its recent approval in over 30 countries which could benefit more than 300,000 patients in the US alone.
The advancements in EYLEA and Dupixent, bolstered by regulatory approvals and new indications, provide strong pipelines for substantial growth in various therapeutic markets.
Dupixent在COPD方面的擴展適應症提供了可觀的市場擴張潛力，考慮到其最近在30多個國家的批准，這可能使僅美國就有超過30萬患者受益。
EYLEA和Dupixent的進展，加上監管批准和新適應症的支持，在各種治療市場上提供了強勁的增長動力。
Risks:
風險：
The market entry and competition from biosimilars for key products such as EYLEA would potentially impact market share and price stabilization.
The ongoing need for heavy investments in R&D for maintaining pipeline momentum and market competitiveness may pressure financial liquidity.
市場進入和生物類似藥對諸如EYLEA等關鍵產品的競爭可能會影響市場份額和價格穩定。
爲保持管道勢頭和市場競爭力，需要大量投資於研發，這可能會對財務流動性造成壓力。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
